ADC Therapeutics S.A.
NYSE: ADCT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ameet Mallik
- Employees
- 263
- Headquarters
- Epalinges, Switzerland
- IPO year
- 2020
- Market cap
- $136.1M
- Website
- https://www.adctherapeutics.com
Loading ADCT…
Loading profile data…Frequently asked questions about ADCT
What does ADC Therapeutics S.A. (ADCT) do?
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-c...
Where does ADCT trade?
ADC Therapeutics S.A. (ADCT) trades on the New York Stock Exchange.
What sector is ADCT in?
ADC Therapeutics S.A. (ADCT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ADC Therapeutics S.A.?
Ameet Mallik is the chief executive officer of ADC Therapeutics S.A. (ADCT).
Where is ADC Therapeutics S.A. headquartered?
ADC Therapeutics S.A. is headquartered in Switzerland.
Does ADCT pay a dividend?
ADC Therapeutics S.A. (ADCT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ADCT go public?
ADC Therapeutics S.A. (ADCT) completed its initial public offering in 2020.